ABU DHABI, United Arab Emirates — Whether a newer class of drugs, the sodium glucose cotransporter 2 (SGLT2) inhibitors, should now be considered as first-line therapy in patients with type 2 diabetes ...

This article was reviewed by Darragh O’Carroll, MD. Diabetes Medications for Weight Loss: What to Know Key takeaways: Some ...

Metformin displayed lowest risk for dementia across diverse antidiabetics, while α-glucosidase inhibitors had highest risk. HealthDay News — Compared with other antidiabetic classes, metformin and ...

In adults with type 2 diabetes (T2D), the use of SGLT2 inhibitors was associated with lower risks for delirium and all-cause mortality than the use of metformin, with more prominent protective effects ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio SAN DIEGO — Sodium-glucose ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — New recommendations from ACP on type 2 diabetes treatment include adding a GLP-1 agonist or SGLT-2 ...

Among patients with type 2 diabetes who have or are at risk for gout, the use of sodium-glucose cotransporter type 2 inhibitors vs sulfonylurea was associated with a lower incidence of gout and ...

A specific type of diabetes medication has been associated with a lower risk of dementia, Alzheimer's and Parkinson's disease in a study published today. The South Korean study followed 358,862 ...

Analysis of more than 1.5 million records of patients with type 2 diabetes casts light on the risk of dementia and Alzheimer’s disease and potential benefits associated with antidiabetic treatment, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In patients with ...